Jasper Therapeutics Inc. (NASDAQ:JSPR) on Thursday said it completed its all-stock acquisition of Kira Pharmaceuticals, bringing the two biotechnology companies together to advance a unified pipeline of therapies targeting immune-mediated and autoantibody-driven diseases.
Jasper Therapeutics Raises $132 Million
In tandem with the merger, Jasper closed a private placement of non-voting convertible preferred stock, raising approximately $132 million in gross proceeds to support its expanded clinical portfolio.
Led by President and CEO Jeet Mahal and CFO Herb Cross, the company anticipates its total capital reserves will fully fund operations through the second half of 2028.
Furthermore, Kira bolstered its corporate balance sheet by out-licensing its KP-301 and KP-402 assets to Mirador Therapeutics in exchange for a $12 million upfront payment plus potential milestone fees.
